Search

Your search keyword '"Allen J. Lehman"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Allen J. Lehman" Remove constraint Author: "Allen J. Lehman"
72 results on '"Allen J. Lehman"'

Search Results

1. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?

2. Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

3. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry

4. Usage and Adherence of Seven Advanced Therapies with Differing Mechanisms of Action for Inflammatory Arthritis in Canada

5. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis

6. Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

7. Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry

8. Long-Term Effectiveness and Safety of Infliximab, Golimumab and Golimumab-IV in Rheumatoid Arthritis Patients from a Canadian Prospective Observational Registry

9. AB0704 EFFECTIVENESS AND SAFETY OF INFLIXIMAB AND GOLIMUMAB IN ANKYLOSING SPONDYLITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY

10. FRI0109 EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND GOLIMUMAB-IV IN RHEUMATOID ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY

11. SAT0393 EFFECTIVENESS AND SAFETY OF INFLIXIMAB, GOLIMUMAB AND USTEKINUMAB IN PSORIATIC ARTHRITIS PATIENTS FROM A PROSPECTIVE OBSERVATIONAL REGISTRY

12. Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

13. AB0436 Consolidated long-term safety of infliximab in inflammatory arthritis from a prospective, observational registry

14. FRI0503 Validation of new potential targets for remission in psoriatic arthritis in patients treated with golimumab

15. Effectiveness and Safety of Infliximab in Rheumatoid Arthritis: Analysis From a Canadian Multicenter Prospective Observational Registry

16. Depressive Symptoms and Rheumatoid Arthritis: Spouse Empathic Responding as a Buffer

17. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies

18. Do spouses know how much fatigue, pain, and physical limitation their partners with rheumatoid arthritis experience? Implications for social support

19. Spouse depression and disease course among persons with rheumatoid arthritis

20. People with arthritis and their families in rehabilitation, care and research

21. Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry

22. Depressive symptoms and rheumatoid arthritis: spouse empathic responding as a buffer

23. Effectiveness and safety of infliximab in rheumatoid arthritis: analysis from a Canadian multicenter prospective observational registry

24. FRI0579 What Is The Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?

25. AB0684 Gender Specific Differences in Ankylosing Spondylitis at Treatment Initiation in Patients Treated with Infliximab or Golimumab: Table 1

26. AB0661 Predictors of Response in Patients with Ankylosing Spondylitis Treated with Infliximab or Golimumab in A Real-World Setting

27. FRI0421 What Is The Location of Enthesitis in Ankylosing Spondylitis and Psoriatic Arthritis Patients and How Do They Respond To Anti-TNF Treatment?: Table 1

28. FRI0473 What Proportion of Patients with PSA Fail To Achieve Mda Based on Patient Reported Outcomes? An Analysis from A Prospective, Observational Registry

29. FRI0467 Predictors of Early Minimal Disease Activity in PSA Patients Treated with Anti-TNF in A Real-World Registry

30. FRI0172 Primary and Secondary Non-Response in RA Patients Treated with An anti-TNF: An Analysis from A Prospective, Observational Registry

31. Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis

32. Minimal clinically important difference for 7 measures of fatigue in patients with systemic lupus erythematosus

33. THU0365 Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice

34. FRI0204 What is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction

35. SAT0338 Does Treatment Improve HAQ or Do Patients Adjust How They Do Things? An Exploration of the HAQ-DI Vs the HAQ-ADI Over Time

36. FRI0036 What is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?

37. SAT0565 Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction

38. AB0304 What Proportion of Patients Fail to Achieve Das, Cdai, Sdai Remission Based on Patient Global assessment? An Analysis from a Prospective, Observational Registry

39. SAT0090 Exploring The Das: What is the Level of Agreement in the Classification of Remission and Low Disease Activity Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? An Analysis from a Prospective, Observational Registry

40. SAT0557 Predictors of Response in Patients with Psoriatic Arthritis Treated with Anti-TNF in a Real-World Setting

41. THU0196 Is the Basdai Score Driven by Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?

42. Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population

43. Determination of the minimal clinically important difference for seven fatigue measures in rheumatoid arthritis

44. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study

45. A randomized double blind, placebo controlled trial of topical Tripterygium wilfordii in rheumatoid arthritis: reanalysis using logistic regression analysis

46. THU0247 What is More Predictive of Achieving Remission at 12 Months: the Percentage of Baseline Improvement or the Actual Disease State Achieved?

47. AB0302 Profile of Joint Involvement over Time in Rheumatoid Arthritis and Psoriatic Arthritis Patients Treated with Anti-TNF in A Real-World Setting

48. SAT0363 Validation of the Ankylosing Spondylitis Disease Activity SCORE (ASDAS) and Effectiveness of Infliximab in the Treatment of Ankylosing Spondylitis over 4 Years

49. THU0241 Predictors of Acr/Eular Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: an Analysis from the Prospective, Observational Registry, Biotrac

50. AB0760 Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: an Analysis from the Prospective, Observational Registry, Biotrac

Catalog

Books, media, physical & digital resources